A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)

Inclusion Criteria:

• Has mild to moderate Alzheimer's Disease (AD) dementia (ie, Stage 4 or Stage 5 AD)based on the Alzheimer's Association Revised Criteria for Diagnosis and Staging ofAlzheimer's Disease

• Has a Mini-Mental State Examination (MMSE) score of 12 to 24 (inclusive)

• Is using acetylcholinesterase inhibitors (AChEI) therapy for management of ADdementia

• Has a designated study partner who can fulfill the requirements of this study. Thestudy partner will need to spend sufficient time with the participant to be familiarwith their overall function and behavior and be able to provide adequate informationabout the participant needed for the study including, knowledge of functional andbasic activities of daily life, work/educational history, cognitive performance,emotional/psychological state, and general health status

Exclusion Criteria:

• Has a known history of stroke or cerebrovascular disease

• Has diagnosis of a clinically relevant central nervous system (CNS) disease otherthan AD dementia or other condition that negatively impacts cognition or cognitivestatus chronically

• Has structural brain disease

• Has a history of seizures or epilepsy

• Has any other major CNS trauma, or infections that affect brain function (eg, Humanimmunodeficiency virus (HIV), syphilis, and/or neurological sequelae of Coronavirusdisease caused by severe acute respiratory syndrome coronavirus 2 (COVID-19),including impact on cognition)

• Has major medical illness or unstable medical condition

• Has a history of malignancy

• Resides in a nursing home or assisted care facility with need for direct continuousmedical care and nursing supervision (with protocol-specified exceptions)

• Has liver disease, including but not limited to chronic viral hepatitis, nonviralhepatitis, cirrhosis, malignancies, autoimmune liver diseases